CLEC9A and neoplasm: IFN-α fused to single domain antibodies targeting Clec9A, a molecule expressed on DCs specialised in cross-priming, displays a potent anti-tumour effect.30 Finally, IFN-α immunocytokines have been demonstrated to exert an anti-tumour effect mediated by the activation of immune system cells.31,32 In summary, type I IFN immunobiology is likely to be exploited in the near future but is not currently in the frontline oncology armamentarium.